News - Alliance Pharma (Alliance), a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, today closed on the purchase of Drug Development Solutions Business (DDS), a UK-based bioanalytical and material science testing contract research organization (CRO), from LGC. Ampersand Capital Partners, a healthcare private equity firm and KKR & Co. Inc. (KKR) (NYSE:KKR) a leading global investment firm, will become equal shareholders in the combined company. This transaction expands bioanalytical, analytical material testing and laboratory capabilities internationally for the biopharma and pharma industry, including areas of cell and gene therapy, next-generation biologics, material sciences and protein characterization.
13 July 2022News - Alliance Pharma, a US-based Bioanalytical CRO and an Ampersand portfolio company, has agreed to acquire DDS, a UK-based Bioanalytical Business Unit of LGC. KKR will become an equal shareholder in the combined business alongside Ampersand Capital Partners. Backed by Ampersand and KKR, Alliance and DDS plan to expand the company’s geographic reach, broaden its laboratory capabilities and expand its service portfolio. The transaction is subject to regulatory approvals and expected to be completed in Q2 2022.
17 May 2022Blog - An understanding of the characteristics of drug exposure following administration and how it relates to safety and efficacy is critical for progressing drug development (e.g. in decision making for drug candidates, design of dosing regimens and making predictions for future studies) as well as being a requirement for regulatory authorities. Pharmacokinetics (PK) analysis aims to evaluate quantitatively how a drug enters the body, what happens to the drug while in the body and ultimately, how it is removed. These processes are commonly referred to by the acronym ‘ADME’, which comprises absorption, distribution, metabolism and excretion.
07 January 2022Blog - Urinary pharmacokinetics (PK) parameters tell you about how much drug was absorbed and how much drug is eliminated
03 January 2022Blog - The area under the concentration vs time curve is a useful description of exposure of drug following administration. There are different ways in which AUC may be calculated, and terminology may vary from one source or text to another. This page summarises the calculations and terminology that may be encountered.
03 January 2022Blog - Meet one of our scientists. Claire is a bioanalytical scientist
06 August 2021Blog - In this infographic, we explore the applications of a flow cytometry-based technique, termed Phosphoflow, for multiplex biomarker analysis and how it can be utilized in a cell-based environment to provide information on a functional and biological level.
12 May 2021Blog - This infographic explores top tips to prolong periods between instrument cleans, compare cleaning times for QqQ and QToF platforms and provide an assessment of robustness, with a focus on sensitivity level and mass accuracy. Finally, it presents common trends to be aware of when the QToF platform has become contaminated and requires cleaning.
07 April 2021Blog - In this video, we look at the benefits and challenges of high res mass spectrometry for the CRO.
08 January 2021News - Drug Development Solutions is pleased to announce the extension of its regulated bioanalytical LC-MS service through the implementation of a high-resolution mass spectrometer, the SCIEX TripleTOF® 6600 LC-MS/MS System.
25 November 2020